Heat-shock proteins (HSPs) derived from
tumors are capable of eliciting an anticancer immune response by facilitating
antigen cross-presentation in antigen-presenting cells (APCs). This process involves the ability of such chaperones to bind
tumor antigens and facilitate their uptake by APCs. Recent evidence reveals that HSP-
tumor antigen complexes bind
cell surface proteins on APCs that mediate complex internalization and antigen-processing events, as well as inducing an innate immune response. Binding of HSPs to surface receptors is, thus, an imposing gateway to the induction of
tumor-specific immune responses. Extensive studies in animals have indicated the usefulness of such HSP-based
immunotherapy in killing established
tumors and causing
tumor regression. Currently, one HSP, the endoplasmic reticulum stress-response
protein Gp96 is undergoing clinical trials for
cancer treatment and has yielded promising results, including the induction of anti-
tumor immunity and some benefit for patients when administered as part of a multidose regimen. Future advances in HSP-based
immunotherapy will be aided by an understanding of the mechanisms by which HSP-
peptide complexes induce innate and adaptive immunity to
tumor cells and target the killing of primary and metastatic
cancer cells.